Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028

Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) - Global Forecast to 2028

The global regenerative medicines market is projected to reach USD 49.0 Billion by 2028 from USD 16.0 Billion in 2023, at a CAGR of 25.1% during the forecast period of 2023 to 2028. Factors such as the wide scope in new therapeutic areas and collaborations and partnerships by major market players are predicted to uplift the market in the coming years. Additionally, rise in the focus of personalized medicine and rising regenerative medicine regulatory approvals will provide lucrative market growth. However, lack of long-term data and ethical and legal concerns and high cost of treatments are predicted to restrict the market.

“The cell therapy segment held the dominant share in the regenerative medicine market.”

Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The increasing popularity of stem therapy is expected to drive the expansion of the cell therapy market.

“Musculoskeletal disorders segment accounted for the largest share of the therapeutic area segment in 2022.”

Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and other applications. This can be attributed to the increasing preavalence of orthopedic disorders and growing interest on musculoskeletal regeneration research.

“APAC region is likely to grow at a faster pace.”

The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. APAC region is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support regenerative medicine market growth in the region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 80%, and Demand Side - 20%

By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

By Region: North America -55%, Europe -10%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

List of Companies Profiled in the Report:

Novartis AG (Switzerland)

Biogen, Inc. (US)

Sarepta Therapeutics, Inc. (US)

Gilead Sciences, Inc. (US)

Amgen Inc. (US)

Smith+Nephew (UK)

MEDIPOST Co., Ltd. (Korea)

JCR Pharmaceuticals Co., Ltd. (Japan)

Takeda Pharmaceutical Company Limited (Japan)

CORESTEM, Inc (South Korea)

Vericel Corporation (US)

MIMEDX Group, Inc. (US)

Organogenesis Inc. (US)

Medtronic (Ireland)

Bristol-Myers Squibb Company (US)

Orthocell Ltd. (Australia)

Mesoblast Ltd. (Australia)

BioRestorative Therapies, Inc. (US)

Pluristem Therapeutics Inc. (US)

TEGOSCIENCE (South Korea)

ANTEROGEN.CO.,LTD. (South Korea)

Bluebird bio, Inc. (US)

Stempeutics Research Pvt Ltd. (India)

Sibiono GeneTech Co. Ltd. (China)

Aspect Biosystems Ltd. (Canada)

Athersys, Inc. (US)

Research Coverage:

This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Growing focus on personalized medicine, steep rise of regulatory approvals in regenerative medicine, rising collaborations and partnerships by major market players, increasing scope in new therapeutic areas), restraints (Lack of long-term data, Ethical and legal concerns and high cost of treatments), opportunities (Integration with artificial intelligence and big data, Harnessing the potential of 3D printing, Growing number of organ transplants) and challenges (Lack of favorable reimbursement policies across various regions) are influencing the growth of regenerative medicine market.

Product Development/Innovation: Detailed insights on newly launched products of the regenerative medicine market.

Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan) and CORESTEM, Inc (South Korea) and among others in the regenerative medicine market.